Stilwell McDavid
SEC CIK 1851389 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| CHRS | Coherus Oncology, Inc. | CFO | 75.3K | — | $58.9K | 7 | 2021-10-15 | 2023-12-31 |
Most active insiders at CHRS, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Ryan Michael Lee | Dir | — | — |
| 2 | McMichael Bryan J | CFO | — | — |
| 3 | O'Donnell-Tormey Jill | Dir | — | — |
| 4 | Newton Charles W. | Dir | — | — |
| 5 | Newcomer Lee Nisley | Dir | — | — |
| 6 | Satvat Ali J. | Dir | — | — |
| 7 | Karachun Rita A | Dir | — | — |
| 8 | Wahlstrom Mats | Dir | — | — |
| 9 | Lanfear Dennis M | Pres, CEO, Dir | — | — |
Stilwell McDavid made no open-market trades at CHRS in the last 12 months.
Transactions 7
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-01-03 | 2023-12-31 | CHRS | Coherus Oncology, Inc. | Stilwell McDavid | CFO | F - Tax | $3.33 | -18.4K | 75.3K | -20% | -$61.4K | |
| 2023-04-04 | 2023-04-01 | CHRS | Coherus Oncology, Inc. | Stilwell McDavid | CFO | F - Tax | $6.84 | -3,457 | 102.3K | -3% | -$23.6K | |
| 2023-01-24 | 2023-01-20 | CHRS | Coherus Oncology, Inc. | Stilwell McDavid | CFO | A - Grant | $0.00 | +40.0K | 104.2K | +62% | $0 | |
| D | 2023-01-06 | 2023-01-04 | CHRS | Coherus Oncology, Inc. | Stilwell McDavid | CFO | F - Tax | $9.87 | -5,437 | 64.2K | -8% | -$53.7K |
| 2022-04-05 | 2022-04-01 | CHRS | Coherus Oncology, Inc. | Stilwell McDavid | CFO | F - Tax | $12.85 | -3,458 | 69.7K | -5% | -$44.4K | |
| D | 2022-01-06 | 2022-01-04 | CHRS | Coherus Oncology, Inc. | Stilwell McDavid | CFO | A - Grant | $0.00 | +40.0K | 73.1K | +121% | $0 |
| 2021-10-19 | 2021-10-15 | CHRS | Coherus Oncology, Inc. | Stilwell McDavid | CFO | S - Sale | $16.80 | -3,507 | 31.6K | -10% | -$58.9K |
Purchase Sale Sale after option exercise All abbreviations